新型抗生素磷酸泰地唑胺的药理作用与临床评价

Pharmacology and clinical evaluation of the new antibiotic tedizolid phosphate

磷酸泰地唑胺(tedizolid phosphate)为新型第2代唑烷酮类抗生素,美国FDA于2014年6月20日批准其用于治疗金黄色葡萄球菌(包括耐甲氧西林菌株、甲氧西林敏感菌株)和各种链球菌属和粪肠球菌等革兰阳性细菌引起的急性细菌性皮肤和皮肤结构感染(ABSSSI)。临床研究表明,该药与利奈唑胺相比具有非劣效性,且安全性较好。本文对磷酸泰地唑胺的药理学、药动学、临床评价和安全性等作一综述。

Tedizolid phosphate is a new second-generation oxazolidinone antibiotic. It was approved for the treatment of Staphylococcus aureus（ including methicillin-resistant strains of methicillin sensitive strain） and various Streptococcus and Enterococcus faecalis and other Gram-positive bacteria causing acute bacterial skin and skin structure infections（ ABSSSI） by the U. S. Food and Drug Administration（ FDA） on June 20,2014. Clinical studies have shown that the drug has noninferiority to linezolid,and its safety is better. Pharmacology,pharmacokinetics,clinical evaluation,and safety of tedizolid phosphate were reviewed in this paper.